United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk - timolol maleate; brinzolamide - eye drops - 5mg/1ml ; 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - timolol maleate; brinzolamide - eye drops - 5mg/1ml ; 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - brinzolamide - eye drops - 10mg/1ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

s.a. alcon-couvreur n.v. - timolol (timolol maleate), brinzolamide - drops eye (suspension) - 5mg/ml+ 10mg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

liqvor cjsc - timolol (timolol maleate), brinzolamide - drops eye (suspension) - 5mg/ml+ 10mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novartis pharma ag, switzerland - timolol maleate,brinzolamide - eye drops, suspension - 5,10 mg/ml,

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515) - brinzolamide ophthalmic suspension 1% is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma. brinzolamide ophthalmic suspension 1% is contraindicated in patients who are hypersensitive to any component of this product. risk summary there are no adequate and well-controlled studies in pregnant women to inform drug-associated risk. in reproductive toxicity studies, brinzolamide administered orally to rats induced fetal toxicity at 375 times the recommended human ophthalmic dose (rhod) based on mg/kg. in rabbits, no fetal toxicity was observed following oral administration (see data) . the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is 2% to 4%, and of miscarriage is 15% to 20%, of clinically recognized pregnancies. data animal data embryo-fetal studies were conduc

United States - English - NLM (National Library of Medicine)

sandoz inc - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515) - brinzolamide ophthalmic suspension 1% is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma. brinzolamide ophthalmic suspension 1% is contraindicated in patients who are hypersensitive to any component of this product. risk summary there are no adequate and well-controlled studies in pregnant women to inform drug-associated risk. in reproductive toxicity studies, brinzolamide administered orally to rats induced fetal toxicity at 375-times the recommended human ophthalmic dose (rhod) based on mg/kg. in rabbits, no fetal toxicity was observed following oral administration (see data). the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is 2% to 4%, and of miscarriage is 15% to 20%, of clinically recognized pregnancies. data animal data embryo-fetal studies were conduct

United States - English - NLM (National Library of Medicine)

oceanside pharmaceuticals. - brinzolamide (unii: 9451z89515) (brinzolamide - unii:9451z89515) - brinzolamide ophthalmic suspension is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (iop) in patients with ocular hypertension or open-angle glaucoma. brinzolamide ophthalmic suspension is contraindicated in patients who are hypersensitive to any component of this product. risk summary there are no adequate and well-controlled studies in pregnant women to inform drug-associated risk. in reproductive toxicity studies, brinzolamide administered orally to rats induced fetal toxicity at 375-times the recommended human ophthalmic dose (rhod) based on mg/kg. in rabbits, no fetal toxicity was observed following oral administration (see data) . the background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the u.s. general population, the estimated background risk of major birth defects is 2% to 4%, and of miscarriage is 15% to 20%, of clinically recognized pregnancies. data animal data embryo-fetal studies were conducted in

New Zealand - English - Medsafe (Medicines Safety Authority)

miro healthcare limited - brinzolamide 10 mg/ml - eye drops, suspension - 1 % - active: brinzolamide 10 mg/ml excipient: benzalkonium chloride carbomer disodium edetate dihydrate hydrochloric acid mannitol sodium chloride sodium hydroxide tyloxapol water for injection - decrease in intraocular pressure in ocular hypertension and open angle glaucoma.